Johnson & Johnson (JNJ) remains a robust investment option, characterized by a secure and growing dividend. Despite facing legal challenges and a slightly lowered earnings outlook, the company’s diversified portfolio, consistent revenue growth, and strong financial health make it a compelling buy for long-term investors.
Revenue and Earnings Growth
Johnson & Johnson has demonstrated consistent financial performance, underscored by its recent earnings reports. In the first quarter of 2024, the company reported a revenue growth of 2.3% to $21.4 billion, with adjusted earnings per share (EPS) of $2.71. The second quarter saw even more impressive results, with worldwide sales increasing by 6.6% to $22.4 billion and adjusted EPS rising by 10.2% to $2.82. Excluding the impact of the COVID-19 vaccine, sales growth was 7.2% worldwide.
This consistent growth is further reflected in the company’s historical performance. Over the past decade, Johnson & Johnson has grown its earnings at a rate of 6.3% annually and is expected to continue this trend with a projected EPS growth rate of 6% per year through 2029. Such steady growth underscores the company’s ability to generate reliable income, which is crucial for maintaining and increasing dividends.
Dividend Payout and Yield
Johnson & Johnson’s dividend history is a testament to its financial stability. The company has increased its dividend for 62 consecutive years, recently announcing a 4.2% increase in the quarterly dividend from $1.19 to $1.24 per share. This brings the dividend yield to approximately 3.40%, making it an attractive option for income-focused investors.
The company’s payout ratio, which measures the proportion of earnings paid out as dividends, is around 46% for
Diversified Portfolio
Johnson & Johnson’s diversified business model is a significant strength. The company operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health. This diversification helps mitigate risks associated with any single market or product line. For instance, the Innovative Medicine segment saw operational sales growth of 8.8% in the second quarter of 2024, driven by products like DARZALEX and TREMFYA. The MedTech segment also experienced growth, with operational sales increasing by 4.4%.
Research and Development
Investment in research and development (R&D) is a cornerstone of Johnson & Johnson’s strategy. The company continues to invest heavily in R&D and strategic acquisitions to drive long-term sustainable growth. Numerous clinical and regulatory milestones were achieved in the second quarter of 2024, highlighting the company’s commitment to innovation. This focus on R&D not only supports the development of new products but also reinforces Johnson & Johnson’s competitive edge in the healthcare industry.
Analyst Ratings and Price Targets
Analysts generally view Johnson & Johnson favorably. The stock is currently rated as a “Buy” by 12 analysts, with an average 12-month price target of $175.17, representing an 11.87% upside from the latest price of $156.58. This optimistic outlook is supported by the company’s consistent revenue growth and strong financial health.
Despite its strengths, Johnson & Johnson faces significant legal challenges, particularly related to talc lawsuits. The company is currently dealing with a potential settlement plan of $6.5 billion. While these legal issues present a risk, it’s important to note that Johnson & Johnson has a history of navigating such challenges effectively. The company’s robust financial position and diversified revenue streams provide a buffer against potential legal liabilities.
Earnings Outlook
While Johnson & Johnson beat second-quarter profit expectations, it lowered its full-year outlook. The company raised its operational sales guidance to $89.2 billion to $89.6 billion but cut its guidance for adjusted EPS to $9.97 to $10.07 from $10.57 to $10.72. This adjustment reflects a cautious approach in light of ongoing legal challenges and market conditions.
Market Valuation
As of July 17, 2024, Johnson & Johnson’s stock price was $156.58, trading near its 52-week low. Despite this, the stock is considered undervalued by some analysts, with Morningstar suggesting it trades at a 469% premium to its fair value estimate of $164 per share. This discrepancy indicates that the market may not fully appreciate the company’s innovation pipeline and growth potential.
In summary, Johnson & Johnson’s dividend is not only safe but also growing, supported by the company’s strong financial performance, diversified portfolio, and commitment to innovation. While legal challenges present a risk, the company’s robust financial health and consistent revenue growth provide a solid foundation for continued dividend increases.
For long-term investors, Johnson & Johnson represents a dependable investment with modest growth potential. The stock’s current undervaluation and attractive dividend yield make it a compelling buy, particularly for those seeking stable income and exposure to the healthcare sector. As the company continues to navigate its legal challenges and invest in future growth, it remains well-positioned to deliver value to its shareholders.
